How has been the historical performance of Genomic Valley?

Answer:The historical performance of Genomic Valley shows significant fluctuations in its financial metrics over the years.

Breakdown:
Genomic Valley's net sales have varied considerably, peaking at 2.72 Cr in March 2023 before dropping to 0.84 Cr in March 2025. The total operating income followed a similar trend, with a high of 2.72 Cr in March 2023 and a decline to 0.84 Cr in March 2025. The company's total expenditure, excluding depreciation, was highest in March 2023 at 1.84 Cr but decreased to 0.41 Cr by March 2025. Operating profit, which reached 0.88 Cr in March 2023, fell to 0.43 Cr in March 2025, while profit before tax showed a similar decline from 0.65 Cr in March 2023 to 0.44 Cr in March 2025. The profit after tax also decreased from 0.65 Cr in March 2023 to 0.36 Cr in March 2025. The earnings per share (EPS) reflected this trend, dropping from 2.13 in March 2023 to 1.18 in March 2025. On the balance sheet, total liabilities decreased from 4.42 Cr in March 2023 to 4.33 Cr in March 2024, while total assets also saw a slight decline from 4.42 Cr to 4.33 Cr in the same period. Overall, Genomic Valley's financial performance has shown volatility, with notable peaks and subsequent declines across various metrics.